- Home
- STVN vs DYN Comparison
STVN vs DYN Comparison
Compare STVN & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STVN | DYN |
|---|---|---|
| Founded | 1949 | 1984 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 4.8B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | STVN | DYN |
|---|---|---|
| Price | $20.69 | $24.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $25.67 | ★ $37.00 |
| AVG Volume (30 Days) | 413.4K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.67 | N/A |
| Revenue Next Year | $9.99 | N/A |
| P/E Ratio | $27.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.89 | $11.92 |
| 52 Week High | $28.00 | $27.31 |
Technical Indicators
Market Signals| Indicator | STVN | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 45.02 |
| Support Level | $20.17 | $16.45 |
| Resistance Level | $20.63 | $26.96 |
| Average True Range (ATR) | 0.74 | 0.89 |
| MACD | -0.26 | -0.28 |
| Stochastic Oscillator | 3.97 | 11.44 |
Price Performance
Historical ComparisonAbout STVN Stevanato Group S.p.A.
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.